{"title":"In vivo study using Amygdalin against mammalian tumors in a mice model","authors":"Ibrahim Abdelwadoud, Afaf eldesoky, Elsayed Salem","doi":"10.21608/bvmj.2023.216116.1669","DOIUrl":null,"url":null,"abstract":"Keywords The present study aimed to evaluate the positive effects of amygdalin against mammalian tumors in vivo . Twenty female albino mice, 4-6 weeks old age, were equally divided into four groups: group I (control) received no drugs; group II (carcinogenic group) received oral 7,12-dimethylbenz[a]anthracene (DMBA) (50 mg/kg b.wt. once a weak) dissolved in sesame oil for 4 weeks; group III (treatment group) received oral amygdalin (0.6 mg/kg b.wt./day) dissolved in 100% corn oil for 4 weeks after DMBA-induced tumor as in group II; group IV (protection group) received amygdalin as in group III prior DMBA administration. The results showed that DMBA-induced mammalian tumors caused a significant increase in serum bilirubin (total and direct). Still, a substantial decrease in serum albumin as a hepatic function was recorded. Serum uric acid as a kidney marker revealed an insignificant increase. In addition, mammalian tissue L-malondialdehyde (L-MDA) concentration showed substantial and a considerable decrease in mammalian tissue total antioxidant capacity (TAC) concentration compared with the control group. However, the administration of amygdalin was able to mitigate DMBA-induced mammalian tumors through decreasing total and direct bilirubin, uric acid concentration, as well as L-MDA concentration, along with a significant increase of TAC concentration in mammalian tissue. Additionally, hematological parameters of amygdalin-administrated mice showed a substantial increase compared to mice with mammalian tumors induced by DMBA. Thus, it can be concluded that amygdalin may successfully protect mammary tumors.","PeriodicalId":8803,"journal":{"name":"Benha Veterinary Medical Journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Benha Veterinary Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/bvmj.2023.216116.1669","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Keywords The present study aimed to evaluate the positive effects of amygdalin against mammalian tumors in vivo . Twenty female albino mice, 4-6 weeks old age, were equally divided into four groups: group I (control) received no drugs; group II (carcinogenic group) received oral 7,12-dimethylbenz[a]anthracene (DMBA) (50 mg/kg b.wt. once a weak) dissolved in sesame oil for 4 weeks; group III (treatment group) received oral amygdalin (0.6 mg/kg b.wt./day) dissolved in 100% corn oil for 4 weeks after DMBA-induced tumor as in group II; group IV (protection group) received amygdalin as in group III prior DMBA administration. The results showed that DMBA-induced mammalian tumors caused a significant increase in serum bilirubin (total and direct). Still, a substantial decrease in serum albumin as a hepatic function was recorded. Serum uric acid as a kidney marker revealed an insignificant increase. In addition, mammalian tissue L-malondialdehyde (L-MDA) concentration showed substantial and a considerable decrease in mammalian tissue total antioxidant capacity (TAC) concentration compared with the control group. However, the administration of amygdalin was able to mitigate DMBA-induced mammalian tumors through decreasing total and direct bilirubin, uric acid concentration, as well as L-MDA concentration, along with a significant increase of TAC concentration in mammalian tissue. Additionally, hematological parameters of amygdalin-administrated mice showed a substantial increase compared to mice with mammalian tumors induced by DMBA. Thus, it can be concluded that amygdalin may successfully protect mammary tumors.